ClinicalTrials.Veeva

Menu
P

Pinnacle Research Group | Anniston, AL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Methotrexate
AC2993
Canakinumab
BI 695501
Vonoprazan
ASN002
Glucose
Ianalumab
Lansoprazole
Xyrem®

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

28 of 137 total trials

A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus (AMETHYST)

In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with cutaneous lupus erythematosus (CLE)....

Enrolling
Subacute Cutaneous Lupus Erythematosus
Chronic Cutaneous Lupus Erythematosus
Drug: Litifilimab
Drug: Placebo

This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3

Enrolling
NASH - Nonalcoholic Steatohepatitis
Drug: Placebo
Drug: IVA337

The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in participants with moderately to severely active pso...

Active, not recruiting
Psoriatic Arthritis
Biological: Placebo
Biological: Risankizumab

The purpose of this study is to evaluate the safety and efficacy of risankizumab in adults with moderately to severely active psoriatic arthritis (Ps...

Active, not recruiting
Psoriatic Arthritis (PsA)
Biological: Placebo
Biological: Risankizumab

The purpose of this study is to evaluate the safety and reactogenicity of mRNA-1195 in healthy adults (18 to 55 years of age).

Active, not recruiting
Epstein-Barr Virus Infection
Biological: Placebo
Biological: mRNA-1195.2

Systemic lupus erythematosus (SLE) is a systemic chronic autoimmune disease characterized by autoantibody production, inflammation, and tissue damage...

Active, not recruiting
Systemic Lupus Erythematosus
Drug: DS-7011a
Drug: Placebo

The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1010, and to evaluate relative vaccine efficacy (rVE) of m...

Enrolling
Seasonal Influenza
Biological: Fluarix®
Biological: Influsplit®

The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have o...

Active, not recruiting
Overweight
Obesity
Drug: Placebo
Drug: Retatrutide

The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe System...

Enrolling
Systemic Lupus Erythematosus
Other: Placebo
Drug: Deucravacitinib

This study will evaluate the efficacy and safety of astegolimab compared with placebo in participants with chronic obstructive pulmonary disease (COP...

Enrolling
Chronic Obstructive Pulmonary Disease (COPD)
Drug: Astegolimab
Drug: Placebo

The primary objective of the study is to determine the relative efficacy of the investigational oral severe acute respiratory syndrome coronavirus 2...

Enrolling
COVID-19
SARS-CoV2
Biological: VXA-CoV2-3.1
Biological: COMIRNATY®

The main purpose of this study is to evaluate the efficacy and safety of Bimagrumab and Tirzepatide, alone or in combination, in adults with obesity...

Enrolling
Overweight
Obesity
Drug: Bimagrumab
Drug: Placebo

This study is researching experimental drugs called trevogrumab and garetosmab (called "study drugs") in combination with another drug, semaglutide (...

Active, not recruiting
Obesity
Drug: Matching Placebo-Trevogrumab
Drug: Matching Placebo-Garetosmab

This study is open to adults who are at least 18 years old and have a body mass index of 27 kg/m² or more. People can take part if they have type 2 d...

Active, not recruiting
Obesity
Diabetes Mellitus, Type 2
Drug: Survodutide
Drug: Placebo

This is an open-label study to evaluate the safety, efficacy, and PK of DNV3837 at a dose of 1.5 mg/kg actual body weight(BW)/day administered via IV...

Enrolling
Clostridium Difficile (C. Difficile)
Drug: DNV3837

This study will evaluate the safety, tolerability, and effects of stimulating the splenic neurovascular bundle (NVB) with the Galvani System, which c...

Enrolling
Rheumatoid Arthritis
Device: Active Stimulation
Device: Sham Stimulation

The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine (SUZ) in participants with pain associated with diabet...

Enrolling
Diabetic Peripheral Neuropathic Pain
Drug: Suzetrigine
Drug: Placebo (matched to Pregabalin)

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab

The purpose of this study is to evaluate long-term safety and tolerability of ianalumab in participants with systemic lupus erythematosus who have pr...

Enrolling
Systemic Lupus Erythematosus
Drug: Placebo
Drug: Ianalumab

The trial will evaluate efficacy, safety and tolerability of ianalumab compared to placebo, given as monthly subcutaneous (s.c.) injection on top of...

Enrolling
Systemic Lupus Erythematosus
Drug: placebo
Drug: ianalumab

Trial sponsors

Lilly logo
Novartis logo
Pfizer logo
AstraZeneca logo
Boehringer Ingelheim logo
AbbVie logo
Amgen logo
Astellas logo
A
MedImmune logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems